Brief: Argenx Advances Clinical Development Of Efgartigimod In Primary Sjogren’s Disease
27/03/2024 06:05
March 27 (Reuters) - argenx SE ARGX.BR :
* ARGENX ADVANCES CLINICAL DEVELOPMENT OF EFGARTIGIMOD IN
PRIMARY
SJOGREN’S DISEASE
* RHO STUDY SUPPORTS PROOF-OF-CONCEPT IN PRIMARY SJOGREN'S
DISEASE
* PLAN TO CONTINUE DEVELOPMENT OF EFGARTIGIMOD TO PHASE 3 IN
ADULTS WITH PRIMARY SJOGREN'S DISEASE (SJD)
Source text for Workspace: urn:newsml:reuters.com:*:nGNE5vps6D
Further company coverage: ARGX.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48587785110;))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles